Structure based ligand design:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Weinheim [u.a.]
Wiley-VCH
1998
|
| Schriftenreihe: | Methods and principles in medicinal chemistry
6 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIV, 153 S. Ill., graph. Darst. |
| ISBN: | 3527293434 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV011767622 | ||
| 003 | DE-604 | ||
| 005 | 20030311 | ||
| 007 | t | ||
| 008 | 980202s1998 gw ad|| |||| 00||| eng d | ||
| 016 | 7 | |a 952799103 |2 DE-101 | |
| 020 | |a 3527293434 |9 3-527-29343-4 | ||
| 035 | |a (OCoLC)40119997 | ||
| 035 | |a (DE-599)BVBBV011767622 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-355 |a DE-19 |a DE-29T |a DE-20 |a DE-91G |a DE-11 |a DE-B768 | ||
| 050 | 0 | |a QP624.75.D77 | |
| 082 | 0 | |a 615.19 |2 21 | |
| 084 | |a VC 6250 |0 (DE-625)147086:253 |2 rvk | ||
| 084 | |a VS 5350 |0 (DE-625)147687:253 |2 rvk | ||
| 084 | |a CHE 828f |2 stub | ||
| 084 | |a CHE 893f |2 stub | ||
| 084 | |a CHE 806f |2 stub | ||
| 245 | 1 | 0 | |a Structure based ligand design |c ed. by Klaus Gubernator ... |
| 246 | 1 | 3 | |a Structure-based ligand design |
| 264 | 1 | |a Weinheim [u.a.] |b Wiley-VCH |c 1998 | |
| 300 | |a XIV, 153 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Methods and principles in medicinal chemistry |v 6 | |
| 650 | 7 | |a Bioactivering |2 gtt | |
| 650 | 7 | |a Bioquimica |2 larpcal | |
| 650 | 2 | |a Conception de médicaments | |
| 650 | 7 | |a Enzyminhibitoren |2 gtt | |
| 650 | 7 | |a Liganden |2 gtt | |
| 650 | 7 | |a Ligands (biochimie) |2 ram | |
| 650 | 2 | |a Ligands | |
| 650 | 7 | |a Ligands |2 ram | |
| 650 | 7 | |a Molecular design |2 gtt | |
| 650 | 7 | |a Quimica farmaceutica |2 larpcal | |
| 650 | 2 | |a Relation structure-activité | |
| 650 | 2 | |a Récepteurs de surface cellulaire - Physiologie | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Drugs |x Design | |
| 650 | 4 | |a Ligand binding (Biochemistry) | |
| 650 | 4 | |a Ligands | |
| 650 | 4 | |a Pharmaceutical chemistry | |
| 650 | 4 | |a QSAR (Biochemistry) | |
| 650 | 4 | |a Receptors, Cell Surface |x physiology | |
| 650 | 4 | |a Structure-Activity Relationship | |
| 650 | 0 | 7 | |a Ligand |0 (DE-588)4035711-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Molekülstruktur |0 (DE-588)4170383-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Proteine |0 (DE-588)4076388-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Enzyminhibitor |0 (DE-588)4152479-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Wirkstoff-Rezeptor-Bindung |0 (DE-588)4190019-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimitteldesign |0 (DE-588)4278218-1 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Proteine |0 (DE-588)4076388-2 |D s |
| 689 | 0 | 1 | |a Ligand |0 (DE-588)4035711-9 |D s |
| 689 | 0 | 2 | |a Molekülstruktur |0 (DE-588)4170383-2 |D s |
| 689 | 0 | 3 | |a Arzneimitteldesign |0 (DE-588)4278218-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Wirkstoff-Rezeptor-Bindung |0 (DE-588)4190019-4 |D s |
| 689 | 1 | 1 | |a Arzneimitteldesign |0 (DE-588)4278218-1 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Enzyminhibitor |0 (DE-588)4152479-2 |D s |
| 689 | 2 | 1 | |a Arzneimitteldesign |0 (DE-588)4278218-1 |D s |
| 689 | 2 | |5 DE-604 | |
| 700 | 1 | |a Gubernator, Klaus |e Sonstige |4 oth | |
| 830 | 0 | |a Methods and principles in medicinal chemistry |v 6 |w (DE-604)BV035418617 |9 6 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007941031&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-007941031 | ||
Datensatz im Suchindex
| _version_ | 1804126310311657472 |
|---|---|
| adam_text | Contents
Preface V
List of Contributors IX
1 Rational Design of Bioactive Molecules
K. Gubernator and H. J. Bohm 1
1.1 Introduction 1
1.1.1 From Ligand Design to Drug Discovery 1
1.2 Source of Structural Information 2
1.3 Classes of Therapeutic Agents 3
1.4 Protein Ligand Interaction 4
1.4.1 Covalent versus Noncovalent Inhibitors 4
1.4.2 Nonbonded Interactions in Protein Ligand Complexes 4
1.4.3 Hydrogen Bonds 5
1.4.4 The Role of Solvent in Polar Protein Ligand Interactions 5
1.4.5 Lipophilic Interactions 7
1.4.6 Criteria for Strong Protein Ligand Interactions 7
1.5 Approaches to Structure Based Ligand Design 8
1.5.1 Ligands Derived from Substrate or Natural Ligand 8
1.5.2 Structures Derived from 3D Database Searches 9
1.5.3 De Novo Design of Ligands 9
1.6 Methods and Tools used in Structure Based Ligand Design 9
1.7 Outlook and Future Developments 10
References 11
2 Examples of Active Areas of Structure Based Design
K. Gubernator and H. J. Bohm 15
2.1 Thrombin Inhibitors 15
2.2 Design of Orally Active Inhibitors of Elastase 19
2.3 Dorzolamide: A Success Story of Structure Based Drug Design 23
2.4 Inhibitors of Serine Esterases 26
2.4.1 Human Pancreatic Lipase (hPL) 26
2.4.2 Model of the Trilaurin Triglyceride Substrate Binding 27
XII Contents
2.4.3 Tetrahydrolipstatin (THL) 28
2.5 Acetylcholinesterase (AChE) 30
2.5.1 Model of the Acetylcholine Substrate Binding 31
2.5.2 Physostigmine 31
2.5.3 EisaiE2020 34
References 35
3 From Renin to HIV 1 Protease
E. A. Lunney and C. Humblet 37
3.1 Introduction 37
3.2 Renin 38
3.2.1 Catalytic Site Binding 41
3.2.2 Backbone Variations 41
3.2.3 Subsite Interdependencies 44
3.2.4 Renin Crystal Structure 50
3.2.5 Summary Renin Modeling 51
3.3 HIV 1 Protease 51
3.3.1 3D Structures of HIV 1 Protease 52
3.3.2 HIV 1 Protease Nonpeptide Inhibitors 55
3.3.3 Docking/Modeling HIV 1 Protease Nonpeptide Inhibitors 59
3.4 Summary: Comparison of HIV 1 Protease versus Renin Structure Based Design 66
3.5 Current Limitations/Future Perspective 67
3.6 Conclusion 68
References 69
4 Zinc Endoproteases: A Structural Superfamily
N. Borkakoti 73
4.1 Introduction 73
4.2 Structural Classification of Zinc Endopeptidase Families 74
4.2.1 Short Spacer or Metzincins Family 74
4.2.2 Long Spacer or Gluzincins Family 78
4.3 Overview of Inhibitor Design 80
4.4 Current Limitations 84
4.5 Future Prospects 85
References 86
5 Structure Based Design of Potent Beta Lactamase Inhibitors
K. Gubernator, I. Heinze Krauss, P. Angehrn, R. L. Charnas, C. Hubschwerlen,
C. Oefner, M. P. G Page and F. K. Winkler 89
5.1 Introduction 89
5.2 Structure of Citrobacter freundii Class C Beta Lactamase 89
5.3 Model of the Mechanism of Action: Cleavage of Penicillin G 90
Contents XIII
5.4 Structure of the Complex with Aztreonam 91
5.5 Design of Inhibitors 95
5.6 Kinetics of the Inhibition Reaction 96
5.7 Hydrolysis by Class A Beta Lactamases 98
5.8 X Ray Structure of the Complex with a Bridged Monobactam 99
5.9 Structure Activity Relationship among Bridged Monobactams KM)
5.10 Conclusion 102
References 102
6 Inhibition of Sialidase
N. R. Taylor 105
6.1 Introduction 106
6.2 Influenza: Disease and Virus 107
6.3 Structure of Sialidase 108
6.4 Mechanism of Catalysis 109
6.5 Binding of Substrate and Transition State Mimics 110
6.6 Structure Based Inhibitor Design 113
6.7 Enzyme Inhibitor Interactions 114
6.8 Inhibitor Potency, Efficacy and Selectivity 116
6.9 Summary 117
Acknowledgements 118
References 118
7 Rational Design of Inhibitors of HIV 1 Reverse Transcriptase
W.Schdfer 119
7.1 Introduction 119
7.2 Building a Model 123
7.3 Test of the Model 124
7.4 Optimization of Compound 3 124
7.5 Design of a New Inhibitor 125
7.6 Guidelines and Conclusions 126
References 127
8 New Computational Approaches to Predict Protein Ligand Interactions
H.J.Bohm 129
8.1 Introduction 129
8.2 The Computer program LUDI 132
8.2.1 Basic Methodology 132
8.2.2 Applications of LUDI 136
8.3 Computational Methods to Predict Ligand Binding Affinities 137
8.3.1 A New Scoring Function for Protein Ligand Complexes 138
8.4 Current Challenges in Computational De Novo Ligand Design 139
XIV Contents
8.5 Summary 140
References 140
9 The Future of Structure Based Design: A Worthy Precept?
H. J. Bohm and K. Gubernator 143
9.1 Introduction 143
9.2 Developments in the Design Process 143
9.3 Screening Systems 145
9.4 Future Prospects 146
Acknowledgement 147
References 147
Index 149
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV011767622 |
| callnumber-first | Q - Science |
| callnumber-label | QP624 |
| callnumber-raw | QP624.75.D77 |
| callnumber-search | QP624.75.D77 |
| callnumber-sort | QP 3624.75 D77 |
| callnumber-subject | QP - Physiology |
| classification_rvk | VC 6250 VS 5350 |
| classification_tum | CHE 828f CHE 893f CHE 806f |
| ctrlnum | (OCoLC)40119997 (DE-599)BVBBV011767622 |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Chemie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03191nam a2200853 cb4500</leader><controlfield tag="001">BV011767622</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20030311 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">980202s1998 gw ad|| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">952799103</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3527293434</subfield><subfield code="9">3-527-29343-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)40119997</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV011767622</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-29T</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-91G</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-B768</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP624.75.D77</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.19</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VC 6250</subfield><subfield code="0">(DE-625)147086:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5350</subfield><subfield code="0">(DE-625)147687:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE 828f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE 893f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE 806f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Structure based ligand design</subfield><subfield code="c">ed. by Klaus Gubernator ...</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Structure-based ligand design</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim [u.a.]</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV, 153 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">6</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bioactivering</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bioquimica</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Conception de médicaments</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Enzyminhibitoren</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Liganden</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ligands (biochimie)</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Ligands</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ligands</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular design</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Quimica farmaceutica</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Relation structure-activité</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Récepteurs de surface cellulaire - Physiologie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ligand binding (Biochemistry)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ligands</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical chemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">QSAR (Biochemistry)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Receptors, Cell Surface</subfield><subfield code="x">physiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Structure-Activity Relationship</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Ligand</subfield><subfield code="0">(DE-588)4035711-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Molekülstruktur</subfield><subfield code="0">(DE-588)4170383-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Proteine</subfield><subfield code="0">(DE-588)4076388-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirkstoff-Rezeptor-Bindung</subfield><subfield code="0">(DE-588)4190019-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimitteldesign</subfield><subfield code="0">(DE-588)4278218-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Proteine</subfield><subfield code="0">(DE-588)4076388-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Ligand</subfield><subfield code="0">(DE-588)4035711-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Molekülstruktur</subfield><subfield code="0">(DE-588)4170383-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Arzneimitteldesign</subfield><subfield code="0">(DE-588)4278218-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Wirkstoff-Rezeptor-Bindung</subfield><subfield code="0">(DE-588)4190019-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimitteldesign</subfield><subfield code="0">(DE-588)4278218-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Arzneimitteldesign</subfield><subfield code="0">(DE-588)4278218-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gubernator, Klaus</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">6</subfield><subfield code="w">(DE-604)BV035418617</subfield><subfield code="9">6</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007941031&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007941031</subfield></datafield></record></collection> |
| id | DE-604.BV011767622 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:15:25Z |
| institution | BVB |
| isbn | 3527293434 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007941031 |
| oclc_num | 40119997 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-29T DE-20 DE-91G DE-BY-TUM DE-11 DE-B768 |
| owner_facet | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-29T DE-20 DE-91G DE-BY-TUM DE-11 DE-B768 |
| physical | XIV, 153 S. Ill., graph. Darst. |
| publishDate | 1998 |
| publishDateSearch | 1998 |
| publishDateSort | 1998 |
| publisher | Wiley-VCH |
| record_format | marc |
| series | Methods and principles in medicinal chemistry |
| series2 | Methods and principles in medicinal chemistry |
| spelling | Structure based ligand design ed. by Klaus Gubernator ... Structure-based ligand design Weinheim [u.a.] Wiley-VCH 1998 XIV, 153 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Methods and principles in medicinal chemistry 6 Bioactivering gtt Bioquimica larpcal Conception de médicaments Enzyminhibitoren gtt Liganden gtt Ligands (biochimie) ram Ligands Ligands ram Molecular design gtt Quimica farmaceutica larpcal Relation structure-activité Récepteurs de surface cellulaire - Physiologie Drug Design Drugs Design Ligand binding (Biochemistry) Pharmaceutical chemistry QSAR (Biochemistry) Receptors, Cell Surface physiology Structure-Activity Relationship Ligand (DE-588)4035711-9 gnd rswk-swf Molekülstruktur (DE-588)4170383-2 gnd rswk-swf Proteine (DE-588)4076388-2 gnd rswk-swf Enzyminhibitor (DE-588)4152479-2 gnd rswk-swf Wirkstoff-Rezeptor-Bindung (DE-588)4190019-4 gnd rswk-swf Arzneimitteldesign (DE-588)4278218-1 gnd rswk-swf Proteine (DE-588)4076388-2 s Ligand (DE-588)4035711-9 s Molekülstruktur (DE-588)4170383-2 s Arzneimitteldesign (DE-588)4278218-1 s DE-604 Wirkstoff-Rezeptor-Bindung (DE-588)4190019-4 s Enzyminhibitor (DE-588)4152479-2 s Gubernator, Klaus Sonstige oth Methods and principles in medicinal chemistry 6 (DE-604)BV035418617 6 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007941031&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Structure based ligand design Methods and principles in medicinal chemistry Bioactivering gtt Bioquimica larpcal Conception de médicaments Enzyminhibitoren gtt Liganden gtt Ligands (biochimie) ram Ligands Ligands ram Molecular design gtt Quimica farmaceutica larpcal Relation structure-activité Récepteurs de surface cellulaire - Physiologie Drug Design Drugs Design Ligand binding (Biochemistry) Pharmaceutical chemistry QSAR (Biochemistry) Receptors, Cell Surface physiology Structure-Activity Relationship Ligand (DE-588)4035711-9 gnd Molekülstruktur (DE-588)4170383-2 gnd Proteine (DE-588)4076388-2 gnd Enzyminhibitor (DE-588)4152479-2 gnd Wirkstoff-Rezeptor-Bindung (DE-588)4190019-4 gnd Arzneimitteldesign (DE-588)4278218-1 gnd |
| subject_GND | (DE-588)4035711-9 (DE-588)4170383-2 (DE-588)4076388-2 (DE-588)4152479-2 (DE-588)4190019-4 (DE-588)4278218-1 |
| title | Structure based ligand design |
| title_alt | Structure-based ligand design |
| title_auth | Structure based ligand design |
| title_exact_search | Structure based ligand design |
| title_full | Structure based ligand design ed. by Klaus Gubernator ... |
| title_fullStr | Structure based ligand design ed. by Klaus Gubernator ... |
| title_full_unstemmed | Structure based ligand design ed. by Klaus Gubernator ... |
| title_short | Structure based ligand design |
| title_sort | structure based ligand design |
| topic | Bioactivering gtt Bioquimica larpcal Conception de médicaments Enzyminhibitoren gtt Liganden gtt Ligands (biochimie) ram Ligands Ligands ram Molecular design gtt Quimica farmaceutica larpcal Relation structure-activité Récepteurs de surface cellulaire - Physiologie Drug Design Drugs Design Ligand binding (Biochemistry) Pharmaceutical chemistry QSAR (Biochemistry) Receptors, Cell Surface physiology Structure-Activity Relationship Ligand (DE-588)4035711-9 gnd Molekülstruktur (DE-588)4170383-2 gnd Proteine (DE-588)4076388-2 gnd Enzyminhibitor (DE-588)4152479-2 gnd Wirkstoff-Rezeptor-Bindung (DE-588)4190019-4 gnd Arzneimitteldesign (DE-588)4278218-1 gnd |
| topic_facet | Bioactivering Bioquimica Conception de médicaments Enzyminhibitoren Liganden Ligands (biochimie) Ligands Molecular design Quimica farmaceutica Relation structure-activité Récepteurs de surface cellulaire - Physiologie Drug Design Drugs Design Ligand binding (Biochemistry) Pharmaceutical chemistry QSAR (Biochemistry) Receptors, Cell Surface physiology Structure-Activity Relationship Ligand Molekülstruktur Proteine Enzyminhibitor Wirkstoff-Rezeptor-Bindung Arzneimitteldesign |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007941031&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV035418617 |
| work_keys_str_mv | AT gubernatorklaus structurebasedliganddesign |